Loss of YAP Protein in Prostate Cancer is Associated with Gleason Score Increase

Abstract

Aims and Background

To investigate the expression of YAP protein by immunohistochemistry in prostate cancer tissues and hyperplasia or normal prostate tissues adjacent to cancer, and establish the correlation of YAP expression with Gleason score.

Methods and Study Design

The expression of YAP protein was evaluated in tissue microarray by immunohistochemistry. The samples included 66 radical prostatectomy specimens with clinically detected prostate cancer and 54 hyperplasia or normal prostate tissues adjacent to cancer.

Results

YAP expression was present mainly in the nuclei of basal cells in both prostate cancer tissues and normal prostate or hyperplasia tissues adjacent to cancer. Cytoplasmic expression of YAP was weaker than nuclear expression in both malignant and nonmalignant luminal epithelial cells. YAP expression was decreased or lost in prostate cancer tissues; hyperplasia or normal prostate tissues adjacent to cancer exhibited stronger nuclear and cytoplasmic expression of YAP (p = 0.0001). Downregulation of YAP expression in prostate cancer samples correlated with Gleason score increase (p = 0.002).

Conclusions

This immunohistochemical study expands our knowledge of the expression and localization of YAP in prostate cancer tissue and nonmalignant prostate tissue adjacent to cancer. YAP might function as a tumor suppressor in prostate cancer. Such information may provide the foundation for the treatment of preneoplastic and neoplastic lesions of the prostate.

Keywords

Gleason scores Immunohistochemistry Prostate cancer YAP

Get full access to this article

View all access options for this article.

References

Siegel

Naishadham

Jemal

Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1): 11–30.

Heidenreich

Aus

Bolla

; European Association of Urology. EAU guidelines on prostate cancer. Eur Urol. 2008; 53(1): 68–80.

Platz

E.A.

Giovannucci

Prostate cancer. In: Schottenfeld

Fraumeni

J.F.

Jr. , eds. Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; 2006: 1151–1165.

Pan

Hippo signaling in organ size control. Genes Dev. 2007; 21(8): 886–897.

Pan

The hippo signaling pathway in development and cancer. Dev Cell. 2010; 19(4): 491–505.

Ramos

Camargo

F.D.

The Hippo signaling pathway and stem cell biology. Trends Cell Biol. 2012; 22(7): 339–346.

Aylon

Ofir-Rosenfeld

Yabuta

The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1. Genes Dev. 2010; 24(21): 2420–2429.

Overholtzer

Zhang

Smolen

G.A.

Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA. 2006; 103(33): 12405–12410.

Levy

Adamovich

Reuven

Shaul

The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death Differ. 2007; 14(4): 743–751.

10.

Yuan

Tomlinson

Lara

Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ. 2008; 15(11): 1752–1759.

11.

Zagurovskaya

Shareef

M.M.

Das

EGR-1 forms a complex with YAP-1 and upregulates Bax expression in irradiated prostate carcinoma cells. Oncogene. 2009; 28(8): 1121–1131.

12.

Kononen

Bubendorf

Kallioniemi

Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4(7): 844–847.

13.

Steinhardt

A.A.

Gayyed

M.F.

Klein

A.P.

Expression of Yes-associated protein in common solid tumors. Hum Pathol. 2008; 39(11): 1582–1589.

14.

Harvey

K.F.

Zhang

Thomas

D.M.

The Hippo pathway and human cancer. Nat Rev Cancer. 2013; 13(4): 246–257.

15.

Sawada

Kiyonari

Ukita

Nishioka

Imuta

Sasaki

Redundant roles of Tead1 and Tead2 in notochord development and the regulation of cell proliferation and survival. Mol Cell Biol. 2008; 28(10): 3177–3189.

16.

Hong

Guan

. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 2012; 23(7): 785–793.

17.

Hélias-Rodzewicz

Pérot

Chibon

YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas. Genes Chromosomes Cancer. 2010; 49(12): 1161–1171.

18.

M.Z.

Yao

T.J.

Lee

N.P.

Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009; 115(19): 4576–4585.

19.

Tufail

Jorda

Zhao

Reis

Nawaz

Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas. Breast Cancer Res Treat. 2012; 131(3): 743–750.

20.

Bai

Zhang

Liang

Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53. Cancer Biol Ther. 2013; 14(6): 511–512.

21.

Alicikus

Z.A.

Yamada

Zhang

Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer. 2011; 117(7): 1429–1437.

22.

Wang

Dong

Zhang

Wang

Qiu

Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci. 2010; 101(5): 1279–1285.

23.

Barry

E.R.

Morikawa

Butler

B.L.

Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature. 2013; 493(7430): 106–110.

24.

Partin

A.W.

Kattan

M.W.

Subong

E.N.

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997; 277(18): 1445–1451.